Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Aardvark Therapeutics, Inc. (AARD : NSDQ)

• Company Description    Aardvark Therapeutics Inc. is a clinical-stage biopharmaceutical company. It focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. The company's lead product candidate includes ARD-101. Aardvark Therapeutics Inc. is based in SAN DIEGO. Number of Employees: 40

• Price / Volume Information    Yesterday's Closing Price: $4.54 Daily Weekly Monthly 20 Day Moving Average: 168,965 shares Shares Outstanding: 21.82 (millions) Market Capitalization: $99.04 (millions) Beta: 5.11 52 Week High: $17.94 52 Week Low: $3.35 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -15.46% -19.59% 12 Week -63.68% -66.42% Year To Date -65.41% -68.41%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 4370 La Jolla Village Drive Suite 1050 - San Diego,CA 92122 USA ph: 858-225-7696 fax: - investorrelations@aardvarktherapeutics.com https://aardvarktherapeutics.com

• General Corporate Information    Officers Tien-Li Lee - Chief Executive Officer and Director Nelson Sun - Chief Financial Officer and Chief Operating Office Jeffrey Chi - Director Roy D. Baynes - Director Susan E. Graf - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 002942100 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/12/26 Share - Related Items Shares Outstanding: 21.82 Most Recent Split Date: (:1) Beta: 5.11 Market Capitalization: $99.04 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.85 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-3.62 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 8.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 15.78% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/12/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.14 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -39.44% vs. Previous Quarter: -22.22% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/26 - -61.71 12/31/25 - -44.59 09/30/25 - -54.90 ROA 03/31/26 - -56.29 12/31/25 - -41.51 09/30/25 - -37.86 Current Ratio 03/31/26 - 8.06 12/31/25 - 10.61 09/30/25 - 12.03 Quick Ratio 03/31/26 - 8.06 12/31/25 - 10.61 09/30/25 - 12.03 Operating Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Net Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Pre-Tax Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Book Value 03/31/26 - 3.99 12/31/25 - 4.90 09/30/25 - 5.64 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00 Debt-to-Capital 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00

Powered by Zacks Investment Research ©